AstraZeneca (LON:AZN) Hits New 52-Week High at $12,488.00

AstraZeneca PLC (LON:AZN) hit a new 52-week high on Monday . The company traded as high as £124.88 ($156.86) and last traded at £121.42 ($152.52), with a volume of 70283445 shares. The stock had previously closed at £119.88 ($150.58).

Wall Street Analyst Weigh In

AZN has been the topic of a number of research analyst reports. Barclays restated an “overweight” rating and issued a £125 ($157.02) target price on shares of AstraZeneca in a research note on Monday, April 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £105 ($131.89) price target on shares of AstraZeneca in a report on Tuesday, April 23rd. BMO Capital Markets reaffirmed an “outperform” rating on shares of AstraZeneca in a report on Monday, February 12th. Jefferies Financial Group reaffirmed a “hold” rating and issued a £110 ($138.17) price target on shares of AstraZeneca in a report on Friday, February 16th. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Monday, April 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of £116.86 ($146.79).

AstraZeneca Price Performance

The business’s fifty day simple moving average is £106.47 and its 200-day simple moving average is £104.59. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70. The firm has a market cap of £189.35 billion, a P/E ratio of 3,980.86, a PEG ratio of 0.89 and a beta of 0.19.

AstraZeneca Increases Dividend

The firm also recently announced a dividend, which was paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd were issued a dividend of GBX 156 ($1.96) per share. This is a boost from AstraZeneca’s previous dividend of $71.80. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a yield of 1.49%. AstraZeneca’s payout ratio is presently 7,524.75%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.